<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="103248"><DrugName>autologous tissue-engineered skin (burns/wounds), Regenicin</DrugName><DrugNamesKey><Name id="43086963">NovaDerm</Name></DrugNamesKey><DrugSynonyms><Name><Value>NovaDerm</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>autologous tissue-engineered skin (burns/wounds), Regenicin</Value></Name></DrugSynonyms><CompanyOriginator id="1057221">Regenicin Inc</CompanyOriginator><CompaniesPrimary><Company id="1057221">Regenicin Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1057221" type="Company"><TargetEntity id="4297889464" type="organizationId">Regenicin Inc</TargetEntity></SourceEntity><SourceEntity id="347" type="ciIndication"><TargetEntity id="D014945" type="MeSH"/></SourceEntity><SourceEntity id="52" type="ciIndication"><TargetEntity id="D002056" type="MeSH"/><TargetEntity id="-672164191" type="omicsDisease"/><TargetEntity id="452" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="CU">Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="347">Wound healing</Indication><Indication id="52">Skin burns</Indication></IndicationsPrimary><ActionsSecondary><Action id="1880">Dermatological agent</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><LastModificationDate>2017-05-25T12:16:34.000Z</LastModificationDate><ChangeDateLast>2016-11-03T00:00:00.000Z</ChangeDateLast><AddedDate>2016-08-31T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1057221" linkType="Company"&gt;Regenicin&lt;/ulink&gt; is developing NovaDerm, an autologous tissue-engineered skin consisting of both epidermal and dermal layers, for the potential treatment of burns and wounds [&lt;ulink linkID="1791437" linkType="Reference"&gt;1791437&lt;/ulink&gt;], [&lt;ulink linkID="1791439" linkType="Reference"&gt;1791439&lt;/ulink&gt;]. By August 2016, the technology had been clinically tested in catastrophic burn patients [&lt;ulink linkID="1791439" linkType="Reference"&gt;1791439&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In August 2016, the US FDA granted Orphan designation to Regenicin's cultured skin substitute (NovaDerm) for the treatment of burns requiring skin grafting [&lt;ulink linkID="1791437" linkType="Reference"&gt;1791437&lt;/ulink&gt;], [&lt;ulink linkID="1792049" linkType="Reference"&gt;1792049&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2016, Regenicin was working with its contract manufacturer in preparation for pre-market approval of NovaDerm by the FDA [&lt;ulink linkID="1791439" linkType="Reference"&gt;1791439&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In October 2016, the company  scheduled a pre-IND meeting with the US FDA Office of Cellular, Tissue and Gene Therapies and the meeting was expected to take place  that month   [&lt;ulink linkID="1806591" linkType="Reference"&gt;1806591&lt;/ulink&gt;]. Later that month, the pre-IND meeting was completed [&lt;ulink linkID="1868746" linkType="Reference"&gt;1868746&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2016, the technology had been clinically tested in over 150 pediatric, catastrophic burn patients [&lt;ulink linkID="1791439" linkType="Reference"&gt;1791439&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1057221">Regenicin Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="52">Skin burns</Indication><StatusDate>2016-08-26T00:00:00.000Z</StatusDate><Source id="1791437" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1057221">Regenicin Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="347">Wound healing</Indication><StatusDate>2016-08-26T00:00:00.000Z</StatusDate><Source id="1791437" type="CORPORATE"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1057221">Regenicin Inc</OwnerCompany><Country id="US">US</Country><Indication id="52">Skin burns</Indication><AwardedIndication>Treatment of burns requiring skin grafting.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-08-22T00:00:00.000Z</MileStoneDate><Source id="1792049" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1057221">Regenicin Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1139580">Pure Med Farma LLC</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="235387" title="Pure Med Farma to supply closed herd collagen to Regenicin for the manufacturing of NovaDerm          "/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>